论文部分内容阅读
目的探讨联合检测血清肿瘤标记物在恶性肿瘤诊断中的价值。方法选择2012年3月至2013年3月某院体检中心进行健康体检及门诊就诊患者共14 280例。根据恶性肿瘤筛查表结果、患者临床症状及阳性体征综合判断,最终确定恶性肿瘤高危人群3 587人,对其血清肿瘤标记物CA125、AFP、CEA、CA19-9、CA72-4、NSE进行检测。对血清肿瘤标记物异常升高患者进行全面检查和长期随访(12个月)。结果随访1年发现恶性肿瘤患者59例,通过Cox回归多因素分析发现,CA125、CEA、CA19-9、CA72-4、NSE是早期筛查恶性肿瘤的危险因素(P<0.05),其中CEA(RR:8.325)、CA19-9(RR:6.761)、CA125(RR:2.231)是重要的危险因素。结论联合检测血清肿瘤标记物有助于癌症的早期诊断、治疗,而且也是恶性肿瘤的危险因素。
Objective To investigate the value of combined detection of serum tumor markers in the diagnosis of malignant tumors. Methods From March 2012 to March 2013, a total of 14 280 cases of physical examination and outpatient treatment in a hospital physical examination center were selected. According to the screening results of malignant tumors, the clinical symptoms and the positive signs of the patients, 3 587 people at high risk of malignant tumor were finally determined, and the serum tumor markers CA125, AFP, CEA, CA19-9, CA72-4 and NSE were detected . Patients with abnormally elevated serum tumor markers undergo a full-scale follow-up and long-term follow-up (12 months). Results Cox regression analysis found that CA125, CEA, CA19-9, CA72-4 and NSE were the risk factors for early screening of malignant tumors (P <0.05). Among them, CEA ( RR: 8.325), CA19-9 (RR: 6.761) and CA125 (RR: 2.231) are important risk factors. Conclusion Combined detection of serum tumor markers contributes to the early diagnosis and treatment of cancer and is also a risk factor for malignancy.